OBJECTIVE AND DESIGN: In an attempt to determine the mechanisms underlying the CD4 T cell expansions in patients receiving intermittent interleukin (IL)-2, a cohort of 10 HIV infected patients were studied during a 5-day cycle of IL-2 to measure rates of apoptosis, the expression of activation markers in CD4 and CD8 T cell subsets and the serum levels of proinflammatory cytokines. All patients were receiving highly active antiretroviral therapy. METHODS: Peripheral blood mononuclear cells were tested pre- and at the completion of IL-2 treatment with annexin V/7-AAD for the measurement of apoptosis. Phenotypic analyses of T lymphocytes were performed in parallel. Serum levels of interferon (IFN)gamma, granulocyte-macrophage colony stimulating factor, IL-6 and tumor necrosis factor (TNF)alpha were tested by enzyme-linked immunosorbent assay. RESULTS: IL-2 increased the spontaneous apoptosis rates of CD4 and CD8 T lymphocytes (P = 0.003). Expression of HLA-DR, CD38 and CD95 increased on both CD4 and CD8 T lymphocytes whereas CD25 induction was observed exclusively on CD4 T cells. Significant increases of serum IL-6 and TNFalpha levels were noted in all patients whereas viral loads remained unchanged. CONCLUSION: Administration of IL-2 for 5 days in HIV infected patients leads to enhanced apoptosis of both CD4 and CD8 T cells despite an eventual increase of the CD4 T cell count. A profound activation state with induction of activation markers on T cells and high levels of TNFalpha and IL-6 accompanies the increased apoptosis during the IL-2 cycle. These data suggest that the CD4 expansions seen in the context of intermittent IL-2 therapy are the net result of increases in both cell proliferation and cell death.
OBJECTIVE AND DESIGN: In an attempt to determine the mechanisms underlying the CD4 T cell expansions in patients receiving intermittent interleukin (IL)-2, a cohort of 10 HIV infectedpatients were studied during a 5-day cycle of IL-2 to measure rates of apoptosis, the expression of activation markers in CD4 and CD8 T cell subsets and the serum levels of proinflammatory cytokines. All patients were receiving highly active antiretroviral therapy. METHODS: Peripheral blood mononuclear cells were tested pre- and at the completion of IL-2 treatment with annexin V/7-AAD for the measurement of apoptosis. Phenotypic analyses of T lymphocytes were performed in parallel. Serum levels of interferon (IFN)gamma, granulocyte-macrophage colony stimulating factor, IL-6 and tumor necrosis factor (TNF)alpha were tested by enzyme-linked immunosorbent assay. RESULTS:IL-2 increased the spontaneous apoptosis rates of CD4 and CD8 T lymphocytes (P = 0.003). Expression of HLA-DR, CD38 and CD95 increased on both CD4 and CD8 T lymphocytes whereas CD25 induction was observed exclusively on CD4 T cells. Significant increases of serum IL-6 and TNFalpha levels were noted in all patients whereas viral loads remained unchanged. CONCLUSION: Administration of IL-2 for 5 days in HIV infectedpatients leads to enhanced apoptosis of both CD4 and CD8 T cells despite an eventual increase of the CD4 T cell count. A profound activation state with induction of activation markers on T cells and high levels of TNFalpha and IL-6 accompanies the increased apoptosis during the IL-2 cycle. These data suggest that the CD4 expansions seen in the context of intermittent IL-2 therapy are the net result of increases in both cell proliferation and cell death.
Authors: Irini Sereti; Hiromi Imamichi; Ven Natarajan; Tomozumi Imamichi; Meena S Ramchandani; Yunden Badralmaa; Steve C Berg; Julia A Metcalf; Barbara K Hahn; Jean M Shen; April Powers; Richard T Davey; Joseph A Kovacs; Ethan M Shevach; H Clifford Lane Journal: J Clin Invest Date: 2005-06-02 Impact factor: 14.808
Authors: Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: S L Pett; C Carey; E Lin; D Wentworth; J Lazovski; J M Miró; F Gordin; B Angus; M Rodriguez-Barradas; R Rubio; G Tambussi; D A Cooper; S Emery Journal: HIV Med Date: 2010-08-31 Impact factor: 3.180
Authors: Sarah W Read; Emily J Ciccone; Peter J Mannon; Michael D Yao; Cheryl L Chairez; Richard T Davey; Joseph A Kovacs; Irini Sereti Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Ven Natarajan; Richard A Lempicki; Irini Sereti; Yunden Badralmaa; Joseph W Adelsberger; Julia A Metcalf; Darue A Prieto; Randy Stevens; Michael W Baseler; Joseph A Kovacs; H Clifford Lane Journal: Proc Natl Acad Sci U S A Date: 2002-07-29 Impact factor: 11.205
Authors: Brian O Porter; Jean Shen; Joseph A Kovacs; Richard T Davey; Catherine Rehm; Jay Lozier; Gyorgy Csako; Khanh Nghiem; Rene Costello; Henry Clifford Lane; Irini Sereti Journal: AIDS Date: 2009-09-24 Impact factor: 4.177
Authors: E J Ciccone; S W Read; P J Mannon; M D Yao; J N Hodge; R Dewar; C L Chairez; M A Proschan; J A Kovacs; I Sereti Journal: Mucosal Immunol Date: 2009-12-02 Impact factor: 7.313